Cancer was a key focus, with programs targeting solid tumors, Lynch syndrome, melanoma, and non-small cell lung cancer.

Shares of Moderna (NASDAQ: MRNA) jumped during the COVID-19 pandemic, but when its COVID-19 vaccine revenue dried up, the ...

Key Points Interested in Moderna, Inc.? Here are five stocks we like better. Moderna shares rose nearly 20% after Science Day ...

Moderna remains a Sell as regulatory setbacks, notably the FDA's Refusal-to-File for mRNA-1010, highlight persistent execution and approval risks. The RTF for mRNA-1010 delays potential influenza ...

Moderna (MRNA) faces major commercial setbacks as mRNA vaccines underperform against traditional competitors in post-pandemic markets. RSV and flu mRNA vaccines struggle with lower durability, higher ...

Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research into a potential bird flu mRNA vaccine, helping to recover some of the ...

Moderna currently has three marketed products in its portfolio — two COVID-19 vaccines (Spikevax and mNexspike) and an RSV vaccine (mResvia). The Zacks Consensus Estimate for overall product sales is ...

Regulatory filings are under review in the U.S., Europe, Canada and Australia, with potential approvals expected to begin in 2026 CAMBRIDGE, MA / ACCESS Newswire / May 6, 2026 / Moderna, Inc.